Antiepileptic Drugs and Visual Function

Pediatric Neurology

Volumn 36, Issue 6, 2007, Pages 353-360

  Verrotti, Alberto ^a   Manco, Rossella ^a   Matricardi, Sara ^a   Franzoni, Emilio ^b   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ATAXIA; ATROPHY; BINOCULAR CONVERGENCE; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CHOROID DETACHMENT; CILIARY BODY EDEMA; CLOSED ANGLE GLAUCOMA; COLOR VISION; COLOR VISION DEFECT; DIPLOPIA; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG WITHDRAWAL; DYSKINESIA; DYSLEXIA; EDEMA; EPILEPSY; EPILEPTIC STATE; EVOKED VISUAL RESPONSE; EYE BLOOD FLOW; EYE IRRITATION; EYE MOVEMENT CONTROL; EYE TRACKING; HUMAN; LENS DISEASE; MONOTHERAPY; MYOPIA; NEUROTOXICITY; NYSTAGMUS; OPHTHALMOPLEGIA; OPTIC DISC ATROPHY; PERIPHERAL RETINAL ATROPHY; PRIORITY JOURNAL; RETINA DISEASE; RETINA INJURY; RETINA MACULOPATHY; RETINOPATHY; REVIEW; SACCADIC EYE MOVEMENT; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SYNAPTIC TRANSMISSION; TREATMENT RESPONSE; VISION; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

ANTICONVULSANTS; CHILD; EPILEPSY; HUMANS; VISION DISORDERS;

EID: 34249899939     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2007.03.001     Document Type: Review

References (93)

1. Hilton E.J., Hosking S.L., and Betts T. The effect of antiepileptic drugs on visual performance. Seizure 13 (2004) 113-128
2. Schwankhaus J.D., Kattah J.C., Lux W.E., Masucci E.F., and Kurtzke J.F. Primidone/phenobarbital-induced periodic alternating nystagmus. Ann Ophthalmol 21 (1989) 230-232
3. A-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med 29 (1997) 275-282 [Erratum in: Ann Med 1997;29:468]
4. Stafanous S.N., Clarke M.P., Ashton H., and Mitchell K.W. The effect of long-term use of benzodiazepine on the eye and retina. Doc Ophthalmol 99 (1999) 55-68
5. Manners T.D., and Clarke M.P. Maculopathy associated with diazepam. Eye 9 (1995) 660-662
6. Hyams S.W., and Keroub C. Glaucoma due to diazepam. Am Psychiatry 134 (1997) 447-448
7. Speeg-Schatz C., Giersch A., Boucart M., et al. Effects of lorazepam on vision and oculomotor balance. Binocul Vis Strabismus Q 16 (2001) 99-104
8. Schwarz D.J., and Grigat G. Phenytoin and carbamazepine: potential- and frequency-dependent block of Na current in mammalian myelinated nerve fibers. Epilepsia 30 (1989) 286-294
9. Chrousos G.A., Cowdry R., Schuelein M., Abdul-Rahim A.S., Matsuo V., and Currie J.N. Two cases of downbeat nystagmus and oscilloscopia associated with carbamazepine. Am J Ophthalmol 103 (1987) 221-224
10. Schwartzman M.J., and Leppik I.E. Carbamazepine-induced dyskinesia and ophthalmoplegia. Cleve Clin J Med 57 (1990) 367-372
11. Berchou R.C., and Rodin E.A. Carbamazepine-induced oculogyric crisis. Arch Neurol 36 (1979) 522-523
12. Noachtar S., Von Maydell B., Fuhry L., and Buttner U. Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side-effects in healthy volunteers. Epilepsy Res 31 (1998) 47-57
13. Yuksel A., Sarslan O., Devranoglu K., et al. Effect of valproate and carbamazepine on visual evoked potential in epileptic children. Acta Pediatr Jpn 37 (1995) 358-361
14. Verrotti A., Trotta D., Cutarella R., Pascarella R., Morgese G., and Chiarelli F. Effects of antiepileptic drugs on evoked potential in epileptic children. Pediatr Neurol 23 (2000) 397-402
15. Lopez L., Thomson A., and Rabinowicz A.L. Assessment of colour vision in epileptic patients exposed to single-drug therapy. Eur Neurol 41 (1999) 201-205
16. Nousiainen I., Kalviainen R., and Mantyjarvi M. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology 107 (2000) 884-888
17. Verrotti A., Lobefalo L., Priolo T., et al. Color vision in epileptic adolescents treated with valproate and carbamazepine. Seizure 13 (2004) 411-417
18. Nousiainen I., Kalviainen R., and Mantyjarvi M. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers. Br J Ophthalmol 84 (2000) 622-625
19. Shorvon S.D. Benzodiazepine: clobazam. In: Levy R.H., Mattson R.H., and Meldrum B.S. (Eds). Antiepileptic drugs. 4th ed. (1995), Raven Press, New York 725-734
20. Keene D.L., Whiting S., and Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 17 (1990) 317-319
21. Gatzonis S., Karadimas P., Gatzonis S., and Bouzas E.A. Clonazepam associated retinopathy. Eur J Ophthalmol 13 (2003) 813-815
22. Wallace S.J. Newer antiepileptic drugs: advantages and disadvantages. Brain Develop 23 (2001) 277-283
23. De Romanis F., and Sopranzi N. Felbamate: a long-term study in subjects with refractory epilepsy [In Italian]. Clin Ter 148 (1997) 83-87
24. Hwang T.L., Still C.N., and Jones J.E. Reversible downbeat nystagmus and ataxia in felbamate intoxication. Neurology 45 (1995) 846
25. Petroff O.A., Rothman D.L., Behar K.L., Lamoureux D., and Mattson R.H. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39 (1996) 95-99
26. Herraz J.L., Sol J.M., and Hernandez J. Gabapentin used in 599 patients with partial seizures: a multicentric observation study. Rev Neurol 30 (2000) 1141-1145
27. Koehler J., Thomke F., Tettenborn B., Stefy R., and Meckers J. Changes in VEP and electroretinogram under anticonvulsive therapy [In German]. Aktuelle Neurol 27 (2000) 484-489
28. Rahman W., Proudlock F., and Gottlob I. Oral gabapentin treatment for symptomatic Heimann-Bielschowsky phenomenon. Am J Ophthalmol 141 (2006) 221-222
29. ++ currents in cortical neurons: functional implication. Eur J Pharmacol 307 (1996) 113-116
30. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia 37 suppl 6 (1996) S4-S11
31. Arndt C.F., Husson J., Derambure P., Hache J.C., Arnaud B., and Defoort-Dhellemmes S. Retinal electrophysiological results in patients receiving lamotrigine monotherapy. Epilepsia 46 (2005) 1055-1060
32. Schachter S.C., Leppik I.E., and Matsuo F. Lamotrigine: a six-month, placebo-controlled, safety and tolerance study. J Epilepsy 8 (1995) 201-209
33. O'Donnell J., and Bateman D.N. Lamotrigine overdose in an adult. J Toxicol Clin Toxicology 38 (2000) 659-660
34. Cereghino J.J., Biton V., and Abou-Khalil B. Levetiracetam for partial seizure: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
35. Loscher W., Honack D., and Bloms-Funke P. The novel antiepileptic drug levetiracetam (ucb L 059) induces alterations in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res 735 (1996) 208-216
36. Hans G., Nguyen L., Rocher V., et al. Levetiracetam: no relevant effect on ionotropic excitatory glutamate receptors. [Abstract]. Epilepsia 41 (2000) 37
37. + channel in rat cortical neurons in culture. Abstr Soc Neurosci 25 (1999) 1868
38. Niespodziany I., Klitgaard H., and Margineanu D.G. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurons of rat hippocampal slices. Neurosci Lett 306 (2001) 5-8
39. Krakow K., Walker M., Otoul C., and Sander J.W.A.S. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56 (2001) 1772-1774
40. Barcs G., Walker E.B., Elger C.E., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41 (2000) 1597-1607
41. Friis M.L., Kristensen O., Boas J., et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 87 (1993) 224-227
42. Wamil A.W., Schmutz M., Portet C., Feldmann K.F., and McLean M.J. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 271 (1994) 301-308
43. Stefani A., Pisani A., De Murtas M., Mercuri N.B., Marciani M.G., and Calabresi P. Action of GP47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 36 (1995) 997-1002
44. Preskorn S.H., and Fast G.A. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 53 (1992) 160-162
45. Schwartzkroin P.A. Cellular electrophysiology of human epilepsy. Epilepsy Res 17 (1994) 185-192
46. Schwartzkroin P.A. Origins of the epileptic state. Epilepsia 38 (1997) 853-858
47. Kalis M.M., and Huff N.A. Oxcarbazepine, an antiepileptic agent. Clin Ther 23 (2001) 680-700
48. Fisher R.S., Eskola J., Blum D., Kerrigan III J.F., Drazkowski J., and Duncan B. Open label pilot study of oxcarbazepine for inpatients under evaluation for epilepsy surgery. Drug Dev Res 38 (1996) 43-49
49. Zaccara G., Gangemi P.F., Messori A., et al. Effects of oxcarbazepine on the central nervous system: computerised analysis of saccadic and smooth pursuit eye movements. Acta Neurol Scand 85 (1992) 425-429
50. DeLorenzo R.J. The epilepsies. In: Bradley W.G., Daroff R.B., Fenichel G.M., Penry J.K., and Glaser G.H. (Eds). Neurology in clinical practice: principles of diagnosis and management. 4th ed. (2004), Butterworth-Heinemann, Philadelphia
51. DeLorenzo R.J., Bowling A.C., and Taft W.C. A molecular approach to the development of anticonvulsants. Ann N Y Acad Sci 477 (1986) 238-246
52. DeLorenzo R.J. Status epilepticus. Curr Ther Neurol 3 (1990) 47-53
53. DeLorenzo R.J. Regulation of neuronal excitability: molecular foundations for the study of alcohol withdrawal. In: Porter R.J., Mattson R.H., Cramer J.A., Taft W.C., and Glaser G.H. (Eds). Alcohol and seizures: basic mechanisms and clinical concepts (1990), F. A. Davis, Philadelphia 47-54
54. Ayala G.F., and Johnston D. The influences of phenytoin of the fundamental electrical properties of simple neural systems. Epilepsia 18 (1977) 299-307
55. Macdonald R.L., and Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia 36 Suppl 2 (1995) S2-S12
56. Hogan R.E., Collins S.D., Reed R.C., and Remler B.F. Neuro-ophthalmological signs during rapid intravenous administration of phenytoin. J Clin Neurosci 6 (1999) 494-497
57. Sandyk R. Total external ophthalmoplegia induced by phenytoin: a case report. S Afr Med J 65 (1984) 141-142
58. Bayer A.U., Thiel H.J., Zrenner E., et al. Color vision test for the early detection of antiepileptic drug toxicity. Neurology 48 (1997) 1394-1397
59. Bergmann A., Bauer I., and Stodiack S. Treatment of epilepsy with tiagabine as add on antiepileptic drug in patients with refractory seizure: experiences in 574 patients. [Abstract]. Epilepsia 41 Suppl 1 (2000) 40
60. Kalviainen R., Hachajc J.C., and Djouardi J. A study of visual fields in patients receiving tiagabine as monotherapy and matched controls receiving carbamazepine or lamotrigine monotherapy. [Abstract]. Epilepsia 41 Suppl 1 (2000) 145
61. Leppik I., Gram L., Deaton R., and Sommerville K.W. Safety of tiagabine: summary of 53 trials. Epilepsy Res 33 (1999) 235-246
62. Fakhoury T., Uthman B., and Abou-Khalil B. Safety of long-term treatment with tiagabine. Seizure 9 (2000) 431-435
63. Krauss G.L., Johnson M.A., Sheth S., and Miller N.R. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 74 (2003) 339-343
64. Krauss G.L. Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsant. Neurology 56 (2001) 140
65. Sorri I., Kalviainen R., and Mantyjarvi M. Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy. Epilepsy Res 67 (2005) 101-107
66. Shank R., Gardocki J.F., Streeter A.J., and Maryanoff B.E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 41 Suppl 1 (2000) S3-S9
67. Banta J.T., Hoffman K., Budenz D.L., Ceballos E., and Greenfield D.S. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 132 (2001) 112-114
68. Nemet A., Nesher R., Almog Y., and Assia E. Bilateral acute angle closure glaucoma following topiramate treatment [In Hebrew]. Harefuah 141 (2002) 597-599 667
69. Craig J.E., Ong T.J., Louis D.L., and Wells J.M. Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. Am J Ophthalmol 137 (2004) 193-195
70. Fraunfelder F.W., Fraunfelder F.T., and Keates E.U. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 111 (2004) 109-111
71. Bhattacharyya K.B., and Basu S. Acute myopia induced by topiramate: report of a case and review of the literature. Neurol India 53 (2005) 108-109
72. Fariello R.G., Varasi M., and Smith M.C. Valproic acid: mechanism of action. In: Levy R.H., Mattson R.H., and Meldrum B.S. (Eds). Antiepileptic drugs. 4th ed. (1995), Raven Press, New York 581-604
73. Löscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 30 (1981) 1364-1366
74. Sorri I., Rissanen E., Mantyjarvi M., and Kalviainen R. Visual function in epilepsy patients treated with initial valproate monotherapy. Seizure 14 (2005) 367-370
75. Ozkul Y., Gurler B., Uckardes A., and Bozlar S. Visual function in epilepsy patients on valproate monotherapy. J Clin Neurosci 9 (2002) 247-250
76. Lippert B., Metcalf B., and Jung M.J. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochem 74 (1977) 441-445
77. Schechter P.J., Trainer Y., and Grove J. Attempts to correlate alterations in brain GABA metabolism by GABA-T inhibitors with their anticonvulsant effects. In: Mandel P., and DeFeudis F.V. (Eds). GABA: biochemistry and CNS functions (1979), Plenum Press, New York 43-45
78. Miller N.R., Johnson M.A., and Paul S.R. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 53 (1999) 2082-2087
79. Mackenzie R., and Klistorner A. Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects occur with vigabatrin. BMJ 316 (1998) 233
80. Constable S., and Pirmohamed M. Drugs and the retina. Expert Opin Drug Saf 3 (2004) 249-259
81. Wild J.M., Martinez C., Reinshagen G., and Harding G.F. Characteristics of a unique visual defect attributed to vigabatrin. Epilepsia 40 (1999) 1784-1794
82. Buncic J.R., Westall C.A., Panton C.M., Munn J.R., MacKeen L.D., and Logan W.J. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111 (2004) 1935-1942
83. Kalviainen R., Nousiainen I., and Mantyjarvi M. Initial vigabatrin monotherapy is associated with increased risk of visual field constriction: a comparative follow-up study with patients on initial carbamazepine monotherapy and healthy controls. Epilepsia 39 Suppl 6 (1998) 72
84. Hardus P., Verduin W.M., Postma G., Stilma J.S., Berendschot T.T.J.M., and Van Veelen C.W.M. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 41 (2000) 581-587
85. Manuchehri K., Goodman S., Siviter L., and Nightingale S. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84 (2000) 499-505
86. Lawden M.C., Eke T., Degg C., Harding G.F., and Wild J.M. Visual field defects associated with vigabatrin treatment. J Neurol Neurosurg Psychiatry 67 (1999) 716-722
87. Malmgren K., Ben-Menachem E., and Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 42 (2001) 609-615
88. Ponjavic V., and Andreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102 (2001) 63-72
89. Besch D., Kurtenbach A., Apfelstedt-Sylla E., et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 104 (2002) 151-170
90. Harding G.F., Spencer E.L., Wild J.M., Conway M., and Bohn R.L. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 23 (2002) 1261-1265
91. Roff Hilton E.J., Cubbidge R.P., Hosking S.L., Betts T., and Comaish I.F. Patients treated with vigabatrin exhibit central visual function loss. Epilepsia 43 (2002) 1351-1359
92. Kinirons P., Cavalleri G.L., O'Rourke D., et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 47 (2006) 311-317
93. Wild J.M., Robson C.R., Jones A.L., Cunliffe I.A., and Smith P.E. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 47 (2006) 917-924